Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.45 |
| ▸ | WNT3A | P56704 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548860 | 0.76 | MAPT (0.53) | CYP1A2KDM4ERAB9APSMD14ALDH1A1 | |
| SCHEMBL1072870 | 0.75 | CFTR (0.54) | RAB9AALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL2978440 | 0.75 | FLT3 (0.63) | KDM4EYTHDC1STAT3HIF1ACTNNB1 | |
| SCHEMBL5908296 | 0.74 | KDM4E (0.57) | CYP1A2KDM4EYTHDC1STAT3HIF1A | |
| SCHEMBL8067938 | 0.72 | CYP1A2 (0.54) | CYP1A2KDM4EYTHDC1STAT3HIF1A | |
| SCHEMBL1962245 | 0.72 | CYP1A2 (0.54) | CYP1A2KDM4EYTHDC1STAT3HIF1A | |
| SCHEMBL3716680 | 0.71 | KDM4E (0.81) | CYP1A2KDM4ESTAT3HIF1ARAB9A | |
| SCHEMBL5792748 | 0.70 | CTNNB1 (0.67) | KDM4EYTHDC1STAT3HIF1ACTNNB1 | |
| SCHEMBL4469917 | 0.70 | IDO1 (0.56) | KDM4EYTHDC1STAT3HIF1ACTNNB1 | |
| SCHEMBL6112119 | 0.70 | CTNNB1 (0.54) | KDM4EYTHDC1STAT3HIF1ACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314590-A1 | Substituted quinolones and methods of use | ChemoCentryx, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1954274-B8 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1954274-B1 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1954274-A4 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1954274-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | CYP1A2 165/4885KDM4E 2670/4885YTHDC1 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.